Knight Diagnostic Laboratories’ expertise in genetics and molecular pathology join together in the diagnosis of inherited cancer syndromes. While most cancer is sporadic, 5-10% of all cancers are inherited. Syndromes may have either recessive or dominant inheritance. Oregon Health and Science University is a center of excellence for Fanconi anemia, a recessive inherited syndrome. Knight Diagnostic Laboratories has been providing comprehensive molecular analyses of the Fanconi genes and other disorders for many years. All inherited cancer syndrome testing is performed and interpreted as described for genetic rare disorders by American College of Medical Genetics.
Showing Results 1 to 10 of 25.

B-Cell IGH Gene Rearrangement

  • Test Code:
    4071
  • Department:
  • Test Synonyms:
    Immunoglobulin (IgH) Gene Rearrangement Immunoglobulin (IgH) Clonality Immunoglobulin light chain clonality Gene rearrangements for B-cell lymphoma B cell gene rearrangement for clonality
View Test

B-Cell IGK Gene Rearrangement

  • Test Code:
    4072
  • Department:
  • Test Synonyms:
    Kappa gene rearrangement Kappa gene clonality Gene rearrangements for B-cell lymphoma B cell gene rearrangement for clonality
View Test

BCR-ABL Kinase Domain Mutations/ABL Sequencing (Qualitative)

  • Test Code:
    4020
  • Department:
  • Test Synonyms:
    Imatinib resistance mutation testing Tyrosine kinase inhibitor resistance mutation testing; ABL mutation testing for chronic myeloid leukemia T3151 Mutation
View Test

BCR-ABL RNA PCR Quantitation for Leukemia

  • Test Code:
    4080
  • Department:
  • Test Synonyms:
    BCR-ABL RNA Philadelphia chromosome fusion transcript levels determination BCR-ABL PCR CML monitoring CML minimal residual disease
View Test

BTK, Exon 14, Sequencing

View Test

CALRETICULIN (CALR) Gene Mutations in Myeloproliferative Neoplasms

View Test

Engraftment (Chimerism) Analysis for Allogeneic Hematopoietic Stem Cell

  • Test Code:
    4380 (Donor Pre-Transplant) 4382 (Recipient Pre-Transplant) 4388 (Post Transplant Chimerism) 4390 (Sorted Cell Chimerism)
  • Department:
  • Test Synonyms:
    Pretransplant DNA storage Post-transplant DNA for engraftment study DNA from sorted cells for chimerism study
View Test

Erythrocytosis Panel

View Test

FLT3 Mutation Analysis

  • Test Code:
    4460
  • Department:
  • Test Synonyms:
    FMS-like tyrosine kinase 3 internal tandem duplication FLT3 D835 FLT3 I836 FLT3 ITD
View Test

GeneTrails Hematologic Malignancies 220 Gene Panel

  • Test Code:
    4600
  • Department:
  • Test Synonyms:
    Heme Malignancies Panel Leukemia Panel Next Gen Sequencing Comprehensive Heme Malignancies Panel Next Gen Sequencing Leukemia Panel ABL1 AKT1 ANKRD26 ARID1A ARID1B ASXL1 ASXL2 ATG2B ATM ATRX BCL2 BCL6 BCOR BCORL1 BIRC3 BIRC6 BLM BRAF BRCA1 BRCA2 BRCC3 BRD4 BTK CALR CARD11 CASP10 CBL CBLB CBLC CCND1 CCND3 CCR4 CD27 CD79A CD79B CDH11 CDKN2A CEBPA CHD2 CHEK2 CREBBP CRLF2 CSF1R CSF3R CTCF CTLA4 CUX1 CXCR4 DAXX DDX41 DDX54 DHX15 DHX29 DIS3 DNAH5 DNAH9 DNAJC21 DNM2 DNMT1 DNMT3A DOCK8 DTX1 EED EFTUD1 EGFR ELANE EP300 ERBB4 ETNK1 ETV6 EZH2 FAM47A FAM5C FAS FAT1 FAT4 FBXO11 FBXW7 FLT3 FOXO1 FYN GATA1 GATA2 GATA3 GNA13 GNAS GNB1 GSKIP HAX1 HIST1H1E HNRNPK HRAS HVCN1 ID3 IDH1 IDH2 IGLL5 IKZF1 IKZF3 IL7R IRF4 JAK1 JAK2 JAK3 KDM6A KIT KLF2 KLHL6 KMT2A KMT2C KMT2D KRAS LLGL2 LRRC4 LUC7L2 MAGT1 MAML1 MAP2K1 MECOM MED12 MEF2B MGA MLH1 MPL MSH2 MSH6 MYC MYD88 NAF1 NBN NF1 NFKBIE NOTCH1 NOTCH2 NPAT NPM1 NRAS NT5C2 NXF1 PAX5 PCLO PDGFRA PHF6 PIGA PIK3CD PIM1 PLCG1 PLCG2 PMS2 POT1 PPM1D PRDM1 PRKCB PRPF40B PRPF8 PRPS1 PSMB5 PTCH1 PTEN PTPN11 RAD21 RB1 RBBP6 RELN RHOA RIT1 RPS15 RTEL1 RUNX1 RYR1 RYR2 SAMD9 SAMD9L SAMHD1 SBDS SETBP1 SETD2 SETDB1 SF1 SF3A1 SF3B1 SH2B3 SMARCA2 SMARCB1 SMC1A SMC3 SOCS1 SPEN SPI1 SRP72 SRSF2 STAG2 STAT3 STAT5B STXBP2 SUZ12 SYK SYNE1 TBL1XR1 TCF3 TCF4 TERC TERT TET2 TNFAIP3 TNFRSF14 TP53 TRAF3 U2AF1 U2AF2 UBR5 USH2A VAV1 WAS WHSC1 WT1 XPO1 ZBTB7A ZRSR2
View Test

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More